Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

inal tract (29%), allergic rhinitis (29%), acne-like skin inflammation (25%), pharyngitis or inflammation of the pharynx (25%), vomiting (25%), abnormal behavior (21%), cough (21%), dry skin (21%), scratching of the skin (21%), external ear infection (21%) and skin infection (21%). The most common Grade 3 AEs (with an incidence of at least 5%) were stomatitis or mouth sores, convulsion and decreased neutrophil count. In addition, single cases of Grade 3 sinusitis, pneumonia, viral bronchitis, gastroenteritis or inflammation of the gastrointestinal tract, limb abscess, aspiration, cyclic neutropenia, post lumbar puncture syndrome, sleep apnea syndrome and dizziness were reported. A single case of Grade 4 convulsion was reported. Adverse events were mostly Grade 1 (mild) or Grade 2 (moderate) in severity and were consistent with those previously reported at six months(11).

About everolimusIn the US, Afinitor® (everolimus) tablets is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Everolimus is approved in Switzerland as Votubia® (everolimus) tablets for the treatment of patients three years of age and older, with SEGA associated with TS, for whom surgery is not a suitable option. Should everolimus be approved in the EU, the trade name will be Votubia.

Afinitor is approved in the US and Switzerland for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and also in the EU for the treatment of patients with advanced RCC whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Afinitor is approved in the US f
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2Insights into the Marketplace and Individual Market Growth 2
... a division of Wyeth (NYSE: WYE ), ... which showed that bazedoxifene/conjugated,estrogens reduced the number and ... up to 80 percent, when compared with placebo. ... Annual Meeting,also showed that bazedoxifene/conjugated estrogens improved symptoms ...
... 4 A new scientific,review released today by ... evidence of benefit is lacking for many common ... dietary supplement,ingredients, a common surgical procedure, and injected ... chondroitin, over-the-counter,dietary supplement ingredients that are used widely ...
Cached Medicine Technology:Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 2Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 3Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 4Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee 2
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader when ... regarding heating, cooling and plumbing services in the greater ... “Queen of Clean” for impressive contractor services in Arizona. ... the years for providing outstanding quality customer service and ... for both homeowners and businesses. Linda Cobb, known as ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... is 700 smiling little faces this holiday that might ... in monetary donations was given to the various charities ... they incur through the year. Some of the charities ... Haven , Shrine's Children's Hospitals, Toys for Tots and ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Risperdal lawsuit ... a mass tort litigation currently underway in Pennsylvania’s Philadelphia ... As of December 24, 2014, court documents indicate that ... behalf of individuals who developed gynecomastia (male breast growth) ... from the Court indicates that this represents an increase ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics ... covers the use of endonuclease-based reporting in PCR and other ... filed a claim in opposition to this patent which was ... Munich on May 28. , , The ...
... ... Leading Healthcare Cost-Management Company , ... Westminster, Colo. (PRWEB) June 16, 2009 -- Silver Creek ... integration and governance announced today that their DataLens™ System was selected by Broadlane®, ...
... SAN FRANCISCO, California, June 16, Autonomy Corporation plc (LSE: ... the enterprise, today announced,that the Greater Cincinnati Behavioral Health ... capture, route, store and manage,its patients records. With Autonomy, ... all of their patients, records online, rather than having ...
... ... better decisions , ... Indianapolis, Indiana (Vocus) June 16, 2009 -- United Benefit Advisors, LLC (UBA), one of ... 2009 UBA Employer Benefit Perspectives survey (video) , which delineates employers, positions ...
... Mike Ramsey, a ... explains the process in his book "Stop Sweating and Start Living." , ... (PRWEB) June 16, 2009 -- If you suffer ... save you money and frustration., , , , ,Written by Mike Ramsey, who first started ...
... ... Manhattan LASIK Center, even though the iLASIK™ Procedure is not without risk, wearing contacts has ... of magnitude more common when compared to the iLASIK procedure. , ... New York, NY (PRWEB) June 16, 2009 -- Board ...
Cached Medicine News:Health News:Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office 2Health News:Broadlane Selects Silver Creek Systems To Accelerate Core Business Analysis And New Client Services 2Health News:Broadlane Selects Silver Creek Systems To Accelerate Core Business Analysis And New Client Services 3Health News:Greater Cincinnati Behavioral Health Services Standardizes on Autonomy's Meaning-Based Technologies 2Health News:Greater Cincinnati Behavioral Health Services Standardizes on Autonomy's Meaning-Based Technologies 3Health News:Employees Increasingly Accept and Understand Reductions in Health Plan Benefits and Premium-Cost Sharing 2Health News:Employees Increasingly Accept and Understand Reductions in Health Plan Benefits and Premium-Cost Sharing 3Health News:Man Discovers Cure for Excessive Sweating 2Health News:Kevin Niksarli, M.D. of Manhattan Lasik Center Reviews Pros and Cons of Contact Lenses vs. iLASIK at an International Meeting on 7/1/2009 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: